London Daily

Focus on the big picture.
Friday, Oct 24, 2025

AstraZeneca's pledge to poorer nations as it seeks COVID jab profits from next year

AstraZeneca's pledge to poorer nations as it seeks COVID jab profits from next year

The pharmaceutical company's chief executive defends the company's decision to start making profits from its COVID-19 vaccine, saying that countries with "low purchasing power" will be spared.

The chief executive of AstraZeneca (AZ) has told Sky News that the company's decision to begin seeking a modest profit from its COVID vaccine is unlikely to kick in until next year.

Pascal Soriot said this was because it still had many doses of the jab to supply that it had promised to do so at cost.

AZ announced earlier this month that it would be seeking to achieve a modest profit in future from the vaccine, in order to fund its new anti-viral COVID treatment.

The company's initial strategy was to provide the jab at cost, designed to help poorer countries get supplies, but the vaccine was also the backbone of the UK's early rollout to older people in late 2020 and early 2021.

But Mr Soriot stressed that, while some countries would be charged above cost for the vaccine, many more would not.
Advertisement

He said: "You have to remember that the orders we are taking today will be delivered next year. We still have a lot of orders at no profit to deliver. So they will be delivered next year.

"So you have got to think of the infection as if you were already in next year. And so essentially most of the world at that point will be in a different phase. And we will be more in a regional epidemic or regional pandemic than a global pandemic.

"But you know, we will of course adapt to every circumstance and countries that have low purchasing power we will be supplied at no profit or very low price and others will be a bit more."

Mr Soriot insisted that he had no regrets that AZ had provided the vaccine at cost, even though some of its competitors, such as Pfizer and Moderna, have supercharged their profits through charges for their COVID vaccines.

He went on: "We always knew that some vaccines would be sold at a profit and we made the decision from day one that we would partner with Oxford and deliver this vaccine around the world at no profit so everybody could access it much as possible.

Vials of COVID vaccines made by AstraZeneca, Pfizer, Johnson and Johnson, and Sputnik V


"And again, we've delivered more than 2 billion doses, 30% of global supply so far, so it really has worked quite well actually. So we always knew that it was what we were going to do. So there is no surprise, so there can't be any regret - it was our plan all along."

Mr Soriot also played down criticism that AZ had received during the pandemic from politicians in Europe, such as the French president Emmanuel Macron, who in January this year claimed that the company's vaccine was "quasi ineffective" in the over-65s.

The AZ chief executive, who declined to comment on why Mr Macron had subsequently changed his mind, suggested that, in fact, the relatively low levels of hospitalisations now being seen in the UK compared with continental Europe might be down to the use of the AZ vaccine in older people.

He noted that, in continental Europe, older patients have mainly been vaccinated with the mRNA vaccine produced by Pfizer.

Mr Soriot added: "Continental Europe vaccinated older people mostly with the mRNA vaccine and the UK vaccinated older people mostly with our vaccine - and we'll have to see over time whether that creates a difference.

"But what is really interesting to see in the data today is that in the UK, the number of hospitalisations…has remained relatively low, even though there were lots of infections, the number of severe infections and hospitalisations was still reasonable, relative to continental Europe, where the number of hospitalisations is relatively high in some countries."

He was speaking as AZ, the largest company in the FTSE 100, formally unveils The Discovery Centre, its new £1bn research and development facility in Cambridge, which will be home to some 2,200 scientists.

The centre, to be opened by the Prince of Wales today, represents the biggest single investment ever made by AZ.

It has been specifically sited in Cambridge to be at the heart of the city's life sciences cluster, within close proximity to the Royal Papworth and Addenbrookes hospitals, Cancer Research UK and the University of Cambridge's school of clinical medicine.

The site is referred to in scientific circles as the 'Nobel factory' as it has created more Nobel Prize winners than anywhere else in the world.

Mr Soriot said AZ spent around $7bn (£5.3bn) on research and development annually - of which "a large proportion", close to one third, is deployed in the UK.

He added: "It's a very substantial investment we make each year."

The opening comes at a hugely busy time for AZ which, earlier this year, completed the $39bn takeover of the rare diseases specialist Alexion.

That took the company, traditionally better known in the industry for its treatments for cancers, heart and respiratory conditions, into a fourth therapy area - and now it has decided, based on the success of its COVID vaccine roll out, to expand into a fifth, vaccines, as well.

However, asked whether AZ was trying to do too much at once, Mr Soriot insisted this was not the case.

He added: "We have great strengths in oncology and we believe we can be one of the three great companies in the world in oncology and maybe even better than that by 2025.

AZ has just achieved its first quarter of $10bn sales


"We continue to do very well in cardiovascular and bio pharmaceuticals overall and now we have rare diseases and vaccines.

"What we call the vaccine and immunotherapy unit is really looking at is managing this portfolio of products to treat or vaccinate people with viral diseases.

"We want to maximise the value of these assets and manage them better.

"Now whether we invest in the long run in this field remains to be seen, but there's a lot of synergies across this portfolio of products."

Mr Soriot pointed out that AZ had just achieved its first quarter during which it had notched up $10bn worth of sales.

It is a significant milestone because, when Mr Soriot oversaw AZ's successful defence against an unwanted takeover approach from Pfizer in 2014, he promised investors that AZ would be delivering annual sales of $40bn a year by 2023.

Comments

mike 4 year ago
Pharmafia and Financial mafia - What's the difference?
Both are unscrupulous and without morality.

Newsletter

Related Articles

0:00
0:00
Close
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
China and Russia Deploy Seductive Espionage Networks to Infiltrate U.S. Tech Sector
Apple’s ‘iPhone Air’ Collapses After One Month — Another Major Misstep for the Tech Giant
Graham Potter Begins New Chapter as Sweden Head Coach on Short-Term Deal
Ecuadorian President Daniel Noboa Alleges Poison Plot via Chocolate and Jam
Lakestar to Halt External Fundraising as Investor in Revolut and Spotify
U.S. Innovation Ranking Under Scrutiny as China Leads Output Outputs but Ranks 10th
Three Men Arrested in London on Suspicion of Spying for Russia
Porsche Reverses EV Strategy as New CEO Bets on Petrol and Hybrids
Singapore’s Prime Minister Warns of ‘Messy’ Transition to Post-American Global Order
Andreessen Horowitz Sets Sights on Ten-Billion-Dollar Fund for Tech Surge
US Administration Under President Donald Trump Reportedly Lifts Ban on Ukraine’s Use of Storm Shadow Missiles Against Russia
‘Frightening’ First Night in Prison for Sarkozy: Inmates Riot and Shout ‘Little Nicolas’
White House Announces No Imminent Summit Between Trump and Putin
US and Qatar Warn EU of Trade and Energy Risks from Tough Climate Regulation
Apple Challenges EU Digital Markets Act Crackdown in Landmark Court Battle
Nicolas Sarkozy begins five-year prison term at La Santé in Paris
Japan stocks surge to record as Sanae Takaichi becomes Prime Minister
This Is How the 'Heist of the Century' Was Carried Out at the Louvre in Seven Minutes: France Humiliated as Crown with 2,000 Diamonds Vanishes
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
×